TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+47.15%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$876M
AUM Growth
+$142M
Cap. Flow
-$21.2M
Cap. Flow %
-2.42%
Top 10 Hldgs %
56.33%
Holding
39
New
2
Increased
1
Reduced
4
Closed
2
Avg Time Held
1.5 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$21.1M
2
DYN icon
Dyne Therapeutics
DYN
+$12.3M
3
ELVN icon
Enliven Therapeutics
ELVN
+$9.43M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$39.2M
2
CMPS icon
Compass Pathways
CMPS
+$11M
3
SLNO icon
Soleno Therapeutics
SLNO
+$6.64M
4
KURA icon
Kura Oncology
KURA
+$4.22M
5
THRD icon
Third Harmonic Bio
THRD
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGON icon
1
CG Oncology
CGON
$5.48B
$95.4M 10.9%
3,670,206
– –
2024 Q1
5 quarters
TNGX icon
2
Tango Therapeutics
TNGX
$3.74B
$55M 6.28%
10,736,000
– –
2024 Q4
2 quarters
COGT icon
3
Cogent Biosciences
COGT
$4.88B
$50M 5.71%
6,964,375
– –
2021 Q4
14 quarters
OCUL icon
4
Ocular Therapeutix
OCUL
$1.58B
$49.4M 5.64%
5,319,148
– –
2024 Q1
5 quarters
CDTX icon
5
DELISTED
Cidara Therapeutics
CDTX
$49M 5.6%
1,005,901
– –
2024 Q4
2 quarters
ABVX icon
6
Abivax
ABVX
$7.68B
$46.3M 5.29%
6,056,596
– –
2023 Q4
6 quarters
AMLX icon
7
Amylyx Pharmaceuticals
AMLX
$3.39B
$38.1M 4.35%
5,943,812
– –
2024 Q3
3 quarters
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$38M 4.34%
2,890,816
– –
2023 Q3
7 quarters
FULC icon
9
Fulcrum Therapeutics
FULC
$280M
$36.1M 4.13%
5,250,000
– –
2024 Q3
3 quarters
DYN icon
10
Dyne Therapeutics
DYN
$2.81B
$35.9M 4.1%
3,766,660
+1,116,510
+42% +$12.3M
2023 Q1
9 quarters
EYPT icon
11
EyePoint Inc
EYPT
$259M
$33.6M 3.84%
3,572,335
– –
2024 Q2
4 quarters
UPB icon
12
Upstream Bio Inc
UPB
$187M
$30.8M 3.51%
2,801,763
– –
2024 Q4
2 quarters
SVRA icon
13
Savara
SVRA
$978M
$28.2M 3.22%
12,362,205
– –
2023 Q3
7 quarters
DNTH icon
14
Dianthus Therapeutics
DNTH
$4.18B
$28M 3.2%
1,501,624
– –
2024 Q4
2 quarters
TYRA icon
15
Tyra Biosciences
TYRA
$1.29B
$27.7M 3.17%
2,898,103
– –
2021 Q4
14 quarters
IRON icon
16
Disc Medicine
IRON
$2.14B
$24.6M 2.81%
465,257
– –
2024 Q2
4 quarters
TRML icon
17
DELISTED
Tourmaline Bio
TRML
$23.6M 2.7%
1,477,593
– –
2023 Q4
6 quarters
AGIO icon
18
Agios Pharmaceuticals
AGIO
$1.85B
$23.2M 2.65%
+697,003
New +$21.1M
2025 Q2
0 quarters
GPCR icon
19
Structure Therapeutics
GPCR
$1.56B
$22M 2.52%
1,063,000
– –
2023 Q1
9 quarters
XNCR icon
20
Xencor
XNCR
$1.74B
$19.3M 2.2%
2,452,138
– –
2024 Q3
3 quarters
SLN icon
21
Silence Therapeutics
SLN
$558M
$17.6M 2.01%
3,033,560
– –
2022 Q3
11 quarters
SLNO icon
22
DELISTED
Soleno Therapeutics
SLNO
$15.6M 1.78%
186,250
-88,750
-32% -$6.64M
2024 Q1
5 quarters
ATXS icon
23
DELISTED
Astria Therapeutics
ATXS
$14.8M 1.69%
2,761,861
– –
2024 Q1
5 quarters
RAPT icon
24
DELISTED
RAPT Therapeutics
RAPT
$13.1M 1.5%
1,636,275
– –
2024 Q4
2 quarters
THRD icon
25
DELISTED
Third Harmonic Bio
THRD
$10.4M 1.19%
1,915,424
-590,000
-24% -$2.94M
2024 Q3
3 quarters
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q2 2025 Portfolio in Review

As of Q2 2025, TCG Crossover Management held 39 positions worth $876M, up 19% from $733M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

TCG Crossover Management's Q2 2025 filing shows 2 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Agios Pharmaceuticals: 697,003 shares worth $23.2M. The largest sale was Mineralys Therapeutics, an estimated $39.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TCG Crossover Management's largest Q2 2025 buy was Agios Pharmaceuticals: 697,003 shares worth $23.2M.
  • TCG Crossover Management added most to Dyne Therapeutics in Q2 2025, an estimated $12.3M increase.
  • TCG Crossover Management's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $6.64M.
  • TCG Crossover Management fully exited Mineralys Therapeutics in Q2 2025, selling an estimated $39.2M.
  • TCG Crossover Management's ten largest holdings make up 56% of its $876M portfolio in Q2 2025.
  • TCG Crossover Management opened 2 new positions and closed 2 in Q2 2025.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $876M.

Based on TCG Crossover Management's 13F filing for Q2 2025, filed 14 Aug 2025.